Baricitinib in the treatment of systemic lupus erythematosus: a systematic review of randomized controlled trials

• Published in: Annals of medicine and surgery 2024-08, Vol.86 (8), p.4738-4744
• Main Authors: Shah, Hussain Haider, Ashfaque, Faiza, Hadi, Zeenat, Waseem, Radeyah, Rauf, Sameer Abdul, Hussain, Tooba, Anas, Zahra, Zehra, Syeda Alishah, Hussain, Muhammad Sheheryar, Wasay Zuberi, Muhammad Abdul, Haque, Md Ariful
• Format: Article
• Language: English
• Subjects: Reviews
• ISSN: 2049-0801; 2049-0801
• DOI: 10.1097/MS9.0000000000002298

Baricitinib, a Janus Kinase (JAK) inhibitor, has emerged as a potential therapeutic option for systemic lupus erythematosus (SLE). This systematic review aims to synthesize evidence from randomized controlled trials (RCTs) evaluating the potential of baricitinib in treating SLE. A systematic search was conducted across electronic databases to identify relevant RCTs assessing baricitinib in patients with SLE. Studies reporting outcomes such as the Systemic Lupus Erythematosus Responder Index-4 (SRI-4), adverse events, and safety profiles were included. Data extraction and quality assessment were performed following PRISMA guidelines. A total of four studies were evaluated for efficacy and safety of baricitinib therapy. Three studies reported SRI-4, British Isles Lupus Assessment Group (BILAG), and Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), except for Dorner and colleagues Only Dorner and colleagues and Wallace and colleagues discuss the anti-dsDNA titres following treatment with baricitinib. The findings consistently demonstrated improved efficacy of baricitinib compared to placebo, particularly in terms of SRI-4 scores. Higher dosages of baricitinib showed significant improvement in disease activity and severity indices. Adverse events, including infections and gastrointestinal disturbances, were reported. Baricitinib holds promise for treating SLE, but caution is needed due to potential adverse events. Careful patient selection and monitoring are crucial. Future research should prioritize long-term safety and comparative effectiveness studies to better understand baricitinib's role in managing SLE.